Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

2024 full-year revenue guidance raised by US$ 2 billion

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)

Gland Pharma appoints Satnam Singh Loomba as COO

Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.

Gland Pharma receives approval for cetrorelix acetate for injection

AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment

Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%